HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Alleviating the storm: ruxolitinib in HLH.

Abstract
In this issue of Blood, Das and colleagues report their results on the use of the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib in murine models of hemophagocytic lymphohistiocytosis (HLH), and the HLH-sibling macrophage activation syndrome (MAS).
AuthorsPaul La Rosée
JournalBlood (Blood) Vol. 127 Issue 13 Pg. 1626-7 (Mar 31 2016) ISSN: 1528-0020 [Electronic] United States
PMID27034417 (Publication Type: Journal Article, Comment)
Chemical References
  • Pyrazoles
  • Janus Kinases
Topics
  • Animals
  • Inflammation (prevention & control)
  • Janus Kinases (antagonists & inhibitors)
  • Lymphocyte Activation (drug effects)
  • Lymphohistiocytosis, Hemophagocytic (genetics, pathology)
  • Pyrazoles (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: